Histone deacetylases as therapeutic targets in hematologic malignancies

Current Opinion in Hematology

Volumn 9, Issue 4, 2002, Pages 322-332

  Melnick, Ari ^a   Licht, Jonathan D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HYBRID PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; ENZYME INHIBITOR; ISOENZYME;

BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CHROMATIN; CHROMOSOME TRANSLOCATION; GENE ACTIVATION; GENE CONTROL; GENE FUNCTION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; LYMPHATIC LEUKEMIA; MYELOID LEUKEMIA; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; FORECASTING; GENETICS; PHYSIOLOGY;

ANIMAL; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FORECASTING; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASES; HUMAN; ISOENZYMES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS;

EID: 0036014986     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200207000-00010     Document Type: Review

References (97)

1. Sodium butyrate inhibits histone deacetylation in cultured cells
2. Butyric acid modulates developmental globin gene switching in man and sheep
3. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease
4. Histone deacetylase inhibitors as new cancer drugs
5. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
6. A transcriptional co-repressor that interacts with nuclear hormone receptors
7. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p
8. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
9. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
10. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid
11. Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins
12. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
13. The Rb/chromatin connection and epigenetic control: Opinion
14. Negative control of p53 by Sir2alpha promotes cell survival under stress
15. Deacetylation of p53 modulates its effect on cell growth and apoptosis
16. Regulation of transcription factor YY1 by acetylation and deacetylation
17. Acetylation and deacetylation of the promyelocytic zinc finger protein (PLZF) regulated its ability to function as a transcriptional repressor
18. Review: Chromatin structural features and targets that regulate transcription
19. The human histone deacetylase family
20. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression
21. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation
22. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex
23. Functional significance of histone deacetylase diversity
24. Isolation and characterization of a novel class II histone deacetylase, HDAC10
25. Molecular cloning and characterization of a novel histone deacetylase HDAC10
26. Cloning and characterization of a histone deacetylase, HDAC9
27. Role of a novel class II histone deacetylase in normal and leukemia-associated transcriptional repression
28. The histone deacetylase-3 complex contains nuclear receptor corepressors
29. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway
30. Identification of a nuclear domain with deacetylase activity
31. Three proteins define a class of human histone deacetylases related to yeast Hda1p
32. Histone deacetylase 4 possesses intrinsic nuclear import and export signals
33. Sound silencing: The Sir2 protein and cellular senescence
34. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity
35. Enzymatic activities of Sir2 and chromatin silencing
36. Sir2 links chromatin silencing, metabolism, and aging
37. Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1
38. The SMRT N-CoR corepressors are activating cofactors for histone deacetylase 3
39. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription
40. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
41. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
42. Cellular differentiation, cytidine analogs and DNA methylation
43. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
44. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis
45. Sir2p exists in two nucleosome-binding complexes with distinct deacetylase activities
46. MLL repression domain activity is mediated through histone deacetylases HPC2, BMI-1 and CtBP
47. Regulation of activity of the transcription factor GATA-1 by acetylation
48. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases
49. Translating the histone code
50. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails
51. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa
52. The bromodomain: A chromatin browser?
53. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
54. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
55. Methyl-CpG-binding proteins. Targeting specific gene repression
56. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
57. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening
58. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library
59. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
60. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
61. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
62. Chemistry of gene silencing: The mechanism of NAD+-dependent deacetylation reactions
63. Identification of a small molecule inhibitor of Sir2p
64. Histone deacetylase as a new target for cancer chemotherapy
65. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity
66. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects
67. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
68. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
69. Loss of PU-1 expression following inhibition of histone deacetylases
70. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
71. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
72. Translocations of the RARalpha gene in acute promyelocytic leukemia
73. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers
74. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases
75. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression
76. PML-RARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb
77. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17)
78. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
79. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia
80. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells
81. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression
82. Duration of nuclear NF-kappaB action regulated by reversible acetylation
83. BCL-6 in the pathogenesis of non-Hodgkin's lymphoma
84. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control
85. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors
86. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells
87. The histone deacetylase inhibitor depsipeptide (FR901228) induces apoptosis via activation of the caspase 8 pathway concurrent with lysine specific acetylation in chronic lymphocytic leukemia cells
88. Histone deacetylase inhibitors increase p21 (WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression
89. Clinical development of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in aggressive non-Hodgkin's lymphomas (NHL) and Hodgkin's disease
90. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis
91. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report
92. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor
93. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
94. Mobilization of transposons by a mutation abolishing full DNA methylation in Arabidopsis
95. Expression of a human endogenous retrovirus, HERV-K, in the brood cells of leukemia patients
96. Association of SET domain and myotubularin-related proteins modulates growth control
97. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts